MYOS RENS Hires College Football Icon and Inspirational Speaker Eric LeGrand as a Special Advisor for its YOLKED® Sports Nutrition Brand
CEDAR KNOLLS, N.J., Feb. 6, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that it has hiredformer Rutgers University football player Eric LeGrand as a Special Advisor for its Yolked® sports nutrition brand. In an October 2010 college football game against Army, LeGrand suffered a severe spinal cord injury while making a tackle, leaving him paralyzed. Since that time, he has become an inspiration to millions around the world by sharing his story with an unwavering positive perspective and indomitable spirit. "Safe, all-natural products are important for all athletes and that's why I was drawn to Yolked. I can't wait to get to work, to help better improve the muscle recovery of athletes." "MYOS is honored to have Eric as a Special Advisor. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the success of our products, including Yolked®, Physician Muscle Health Formula®, MYOS Canine Muscle Formula®, Qurr® and MYOS Enteral NutritionFormula™, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate revenue and cash flow from sales of our products, the ability to increase our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with the Securities and Exchange Commission.